Genedata Biologics at Eighth Annual PEGS

Share Article

Bayer HealthCare Pharmaceuticals to present on fully automated high-throughput antibody engineering using Genedata Biologics.

Genedata Biologics

Integrated tools for biologics R&D operations

Genedata Biologics, already adopted by more than 25% of world’s leading pharmas and biotechs, is the result of a five-year development program in close collaboration with leading international players in biologics R&D.

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced Genedata Biologics will be a featured technology at the Eighth Annual PEGS. A first-in-class, end-to-end solution for biologics R&D, Genedata Biologics will be showcased in a Bayer HealthCare Pharmaceuticals presentation at the PEGS Engineering Antibodies session. The presentation will detail the implementation of an automated high-throughput biologics screening process for the discovery and optimization of monoclonal antibody leads. Examples of laboratory workflows and data management using the Genedata Biologics software platform will be presented. Genedata Biologics will also be featured in poster sessions at PEGS, the foremost protein engineering summit (Boston Park Plaza Hotel & Towers; April 30 – May 4).

Development of biopharmaceuticals is fundamentally different from classical small molecule drug development. Biologics R&D requires highly specialized, complex, time-consuming, and costly processes, based on sophisticated workflows and novel discovery technologies. Genedata Biologics is a dedicated data management solution tailored to address the specific requirements of the biologics R&D process. Simplifying and streamlining laborious, manual processes such as cloning or instrument operation, the Genedata Biologics platform increases efficiency and throughput. Improved quality of results through the reduction of ad-hoc and error-prone sample and data handling is also realized.

PEGS presentation and poster sessions will examine how Genedata Biologics enables more flexible and ultra high-throughput workflows, and how classic process bottlenecks can be removed. Concrete use cases will include:

  •     HT antibody phage-display;
  •     screening automation;
  •     affinity maturation;
  •     design and evaluation of engineered molecules;
  •     high-throughput expression, purification, and analytics of novel biologics candidates.

“Genedata Biologics, already adopted by more than 25% of world’s leading pharmas and biotechs, is the result of a five-year development program in close collaboration with leading international players in biologics R&D,” noted Dr. Othmar Pfannes, CEO of Genedata. “Through collaboration with leading companies such as Bayer HealthCare, we’ve developed the first, dedicated data management platform for biologics R&D. We are honored to share our findings and software solution with our colleagues at PEGS.”

Editorial Note: On May 3 at 9:35am EST, Genedata Biologics will be featured in the PEGS Engineering Antibodies Discovery Stream presentation “Implementation of a Fully Automated High-Throughput Antibody Engineering Process” by Dr. Christoph Freiberg of Bayer HealthCare Pharmaceuticals. To schedule a briefing contact, jackie(dot)thrasivoulos(at)genedata(dot)com.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US.

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Allison Kurz
+41 61 511 8459
Email >

Jackie Thrasivoulos
+1 508 881 3109
Email >
Visit website